Personalis, a provider of medical exome and genome sequencing and interpretation services, has closed a $22 million Series B round of funding led by Abingworth, which significantly increased its stake in the company. The round included additional participation from Lightspeed Venture Partners, Mohr Davidow Ventures and Wellington Shields & Co. Personalis has now raised over $42 million in funding to date, including a $20.5 million Series A round that valued the company at $36 million in 2011.
The company will use the new capital to build on its platform, expand its product offerings, scale operations and expand its commercial team. Since its first purchase order 13 months ago, Personalis has received more than $14 million in customer orders for the sequencing and analysis of over 7,000 human samples, including whole genome and exome sequencing. Customers include pharmaceutical and integrated healthcare companies, as well as academic and government research laboratories.